Abstract
Diltiazem is a member of a class of pharmacologic agents that block the passage of calcium ions across cell membranes, the calcium‐channel blockers. Several investigators have reported a clinically important pharmacokinetic and pharmacologic interaction between digoxin and verapamil.1–4 Despite earlier suggestions of such an interaction with nifedipine, recent works have convincingly shown that no pharmacokinetic changes occur.5–7 Thus, it appears that nifedipine has no clinically significant interaction with digoxin. Similar work has been limited with diltiazem. A recent investigation by Yoshida and associates,8 suggested no increase in digoxin serum concentration and a slight decrease in renal digoxin clearance after diltiazem had been added versus a control period. Rameis and co‐workers9 recently reported a 22.4% increase in serum digoxin concentration when diltiazem was added. The purpose of this study was to further evaluate this potential interaction.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
